Nov. 12 at 6:32 PM
$OGEN Strengthened Balance Sheet
We are confident that the company's capital increase of US
$16.5 million (gross proceeds) in July 2025, through convertible Series H preferred shares and warrants, provides sufficient funding to advance ONP-002 through Phase IIa trials in Australia and prepare for Phase IIb trials in the US. Following the capital increase:
Net proceeds: approximately US
$15.2 million after fees and expenses
Debt repaid: US
$3 million in liabilities fully settled
NYSE compliance: Equity once again above the US
$6 million threshold
Operational efficiency metrics
Oragenics continued to demonstrate operational discipline during the nine months ending September 30, 2025:
30% reduction in research and development costs (compared to the previous year)
5% reduction in total operating expenses (compared to the previous year)
